API and Intermediate

Nilotinib

Product Name:Nilotinib
Synonyms:Nilotinib(AMN 107);Nilotinib, AMN107, Tasigna;Nilotinib-d6;4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)-phenyl)-3-((4-(pyridin-3-yl)pyrimid;Nilotinib &aMp;4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide Nilotinib (AMN-107);Nilotinib 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide;Nilotinib, >=99%; Nilotinib;Tasigna;Nilotinib (AMN-107);its intermediates;Nilotinib for research;Nilotinib(AMN 107);Nilotinib,AMN107,Tasigna;AMN 107;
CAS:641571-10-0
MF:C28H22F3N7O
MW:529.52
EINECS:700-544-5
Product Categories:AMN-107;Cardiovascular APIs;-;Inhibitors;API;Molecular Targeted Antineoplastic;Nucleotides and Nucleosides;Bases & Related Reagents;Intermediates & Fine Chemicals;Nucleotides;Pharmaceuticals;Pharmaceutical intermediate
Type:Antineoplastic Agents
Grade Standard:Food Grade, Medicine Grade, Tech Grade, Pharma Grade
Appearance:white powder Chemical Properties Off-White Solid
Place of Origin:China
Mol File:641571-10-0.mol
Density:1.36
storage temp.:-20°C Freezer
Form:Beige powder.
HS Code:29335990
PSA:97.62000
LogP:6.50180
Density:1.36 g/cm3
Refractive Index:1.65
Purity:99%
Shelf life:2 Years
Packaging Details: Package:100G;1KG;5KG;10KG;25KG;50KG;100KG Packing Group:III
1) 1kg with plastic container inside/Aluminum foil bag outside. 
2) 25kg with double plastic container inside/Fiber drum outside. 
3) As your request
Sample: Available
Description:Chronic myeloid leukemia (CML), a hematological stem-cell disorder, is definitively diagnosed by the detection of the Philadelphia chromosome, a truncated version of chromosome 22 resulting from the reciprocal translocation of chromosomes 9 and 22 induced by a single mutagenic event. The consequence is the juxtaposition of two genes creating a fusion gene BCR-ABL. This gene leads to the translation of a fusion protein with increased tyrosine kinase activity that contributes to the pathogenesis of CML. Targeting the BCR-ABL protein has led to the successful intervention of the disease. Now established as first-line therapy for CML, imatinib was the first selective tyrosine kinase inhibitor of BCR-ABL. Since imatinib only binds to an inactive conformation of the ABL kinase portion, the conformational restrictions contribute to its selectivity.
Usage:Animal Pharmaceuticals
Uses:Nilotinib (AMN1O7) might be useful in treatment of chronic myelogenous leukemia
Nilotinib (AMN-107) is a Bcr-Abl inhibitor with IC50 less than 30 nM.
Nilotinib-d6, is the labeled analogue of Nilotinib, which might be useful in treatment of chronic myelogenous leukemia.
Nilotinib, in the form of the hydrochloride monohydrate salt, is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia.
Copyright(C)2017, KangRui BIO-TECH Co.,Ltd.(H.K.) All Rights Reserved. Supported by ChinaTexNet TexWeb Toocle Backstage 备案号:浙ICP备09104425号-1
 
点击这里给我发消息
点击这里给我发消息
 
 
 
 
 
My status
David Chen
My status
biopharmonline